

ANSWERING REVIEWERS



Feb 23, 2014

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 7053-review.doc).

Title: Pathogenesis of liver cirrhosis

Authors: Wen-Ce Zhou, Quan-Bao Zhang, Liang Qiao

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 7053

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

(1) Reviewer 1

Comments: *Authors are kindly requested to emphasize NAFLD and quote the following studies.*

Response: NAFLD is an important cause for cirrhosis worldwide. In the revised manuscript, the following references were quoted:

[20] Lazo M, et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. *BMJ* 2011; 343: d6891.

[21] Ekstedt M, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. *Hepatology* 2006; 44: 865-873. [22] Tarantino G, et al. Serum Bcl-2 concentrations in overweight-obese subjects with nonalcoholic fatty liver disease. *World J Gastroenterol* 2011;17:5280-5288.

[23] Tarantino G, et al. Circulating levels of cytochrome C, gamma-glutamyl transferase, triglycerides and unconjugated bilirubin in overweight/obese patients with non-alcoholic fatty liver disease. *J Biol Regul Homeost Agents* 2011;25(1):47-56.

[112] Tarantino G, et al. Could inflammatory markers help diagnose nonalcoholic steatohepatitis? *Eur J Gastroenterol Hepatol.* 2009;21:504-511.

[113] Tarantino G, et al. Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. *World J Gastroenterol* 2010;16:4773-4783.

[136] Kawaguchi K, et al. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. *Biochem Biophys Res Commun* 2004;315:187-195.

[137] Ibañez P, et al. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. *J Gastroenterol Hepatol* 2007;22:846-851.

[138] Mazo DF, et al. S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis. *Drug Des Devel Ther* 2013;7:553-563.

[139] Jia X, et al. Dysregulated bile acid synthesis, metabolism and excretion in a high fat-cholesterol diet-induced fibrotic steatohepatitis in rats. *Dig Dis Sci* 2013;58:2212-2222.

(2) Reviewer 2

Comments:

The article intituled "Pathogenesis of liver cirrhosis" summarize the current understanding of the molecular pathogenesis of FIBROSIS and liver cirrhosis. The article is suitable of publication, however, the text need revision and it is necessary the inclusion of "fibrosis and cirrhosis therapies" and "animal models of cirrhosis" topics. It is recommended another tittle.

Response:

Thank you for your suggestion. In the revised manuscript, we added two parts to introduce the current advance in "animal models of cirrhosis" and "fibrosis and cirrhosis therapies".

(3) Reviewer 3

Comments:

1. Basic rules of writing manuscript is not followed.
2. New information is lacking.
3. Aim and conclusions are not matching

Response:

The manuscript has been thoroughly revised.

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

W. C. Zhou

The Department of General Surgery II,
the First Hospital of Lanzhou University,
Lanzhou 730000, China.

E-mail: zhouwc129@163.com

Telephone: +86-931-8625200

Fax: +86-931-8619797